Teva raises Copaxone price 10% (#msg-83178715), but this was already baked into Teva’s prior guidance, which implies about $2.9B of US Copaxone sales in 2013 (#msg-81977344).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.